Teligent Inc (NASDAQ:TLGT) has been given a consensus broker rating score of 2.20 (Buy) from the five brokers that cover the company, Zacks Investment Research reports. Three research analysts have rated the stock with a hold rating and two have given a strong buy rating to the company.
Analysts have set a twelve-month consensus price target of $9.25 for the company and are anticipating that the company will post ($0.02) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Teligent an industry rank of 82 out of 265 based on the ratings given to its competitors.
Teligent (NASDAQ:TLGT) opened at 8.90 on Monday. The stock has a market capitalization of $470.56 million and a PE ratio of 143.55. Teligent has a 52 week low of $8.80 and a 52 week high of $9.07. The stock has a 50 day moving average price of $0.00 and a 200 day moving average price of $0.00.
TLGT has been the subject of a number of research analyst reports. Zacks Investment Research raised Teligent from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a research report on Wednesday, December 30th. JMP Securities initiated coverage on Teligent in a research report on Wednesday, September 9th. They issued a “market perform” rating for the company.
IGI Laboratories, Inc. is a specialty generic pharmaceutical company. Under its IGI label, the Company sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (NASDAQ:TLGT) and cosmetic industries. The Company has two platforms for growth: developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its current contract manufacturing and formulation services business. The Company also develops, manufactures, fills and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as the OTC and cosmetic markets. These products are used in a range of applications from cosmetics to the prescription treatment of conditions like dermatitis, psoriasis and eczema.
For more information about research offerings from Zacks Investment Research, visit Zacks.com